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Edited by Varda RotterAbstract The majority of human prostate cancer cell lines,
including the two ‘‘classical’’ cell lines DU-145 and PC-3, are re-
ported to be androgen receptor (AR)-negative. However, other
studies have provided evidence that the DU-145 and PC-3 cell
lines express AR mRNA. These contradictory observations
prompted us to investigate whether DU-145 and PC-3 cell lines
express the androgen receptor. Using antipeptide antibodies di-
rected against three distinct regions of the human AR protein
and an improved method to detect AR protein in immunoblot-
ting, we report that DU-145 and PC-3 cell lines express AR pro-
tein. We found that the relative levels of the AR mRNA and
protein that were detected in DU-145 and PC-3 cell lines were
lower than the LNCaP, an AR-positive cell line. Moreover, the
antibody directed against the non-variant region (amino acids
299–315), but not the variant N- or C-terminal region (amino
acids 1–20 and 900–919, respectively) of the human AR protein,
detected the expression of AR in all prostate cancer cell lines.
Notably, treatment of these cell lines with dihydrotestosterone
(DHT) resulted in measurable increases in the AR protein levels
and considerable nuclear accumulation. Although, treatment of
DU-145 and PC-3 cells with DHT did not result in stimulation
of the activity of an AR-responsive reporter, knockdown of AR
expression in PC-3 cells resulted in decreases in p21CIP1 protein
levels, and a measurable decrease in the activity of the p21-
luc-reporter. Our observations demonstrate the expression of
AR protein in DU-145 and PC-3 prostate cancer cell lines.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Androgens; Androgen receptor; Prostate cancer;
Androgen-independent1. Introduction
Androgen signaling plays a critical role in the normal devel-
opment, proliferation, and diﬀerentiation of the prostate gland
[1,2]. Androgens signal via the intracellular androgen receptor
(AR), a member of the superfamily of nuclear hormone recep-
tors. It is generally accepted that androgen binding to the AR*Corresponding author. Fax: +1 708 202 2647.
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translocation to the nucleus, which is followed by binding to
speciﬁc response elements in the promoter regions of target
genes to modulate gene expression either positively or nega-
tively [1,2]. However, other reports have suggested that AR-
mediated transcription of genes could be induced in response
to growth factors, such as epidermal growth factor, insulin like
growth factor-1 (IGF-1), keratinocyte growth factor [3], and
cytokines like IL-6 in a ligand-independent manner [4].
Although, the majority of human prostate cancer cell lines
are reported to be AR-negative [5–7], several studies have indi-
cated that DU-145 and PC-3 prostate cancer cell lines express
detectable levels of the AR mRNA [8–12]. Moreover, treat-
ment of DU-145 and PC-3 cells with natural b-interferon
(IFN), a potent negative regulator of cell growth in vitro and
in vivo [13], resulted in upregulation of the AR protein levels
[14,15].
Like other steroid hormone receptors, the AR is a phospho-
protein [16]. It is generally accepted that phosphorylation of
AR protein serves several functions, including both its activa-
tion and stabilization [17]. In LNCaP cells, the AR protein is
detected as two isoforms with apparent molecular masses of
110 and 112 kDa [18]. The 112 kDa isoform of AR protein is
shown to be a phosphorylated form [18]. Interestingly, phos-
phorylation of AR protein appears to be regulated in cell-type
speciﬁc manner [19]. It is currently unclear whether diﬀerent
functions of the AR protein are linked to diﬀerent phosphory-
lation sites or whether phosphorylation of AR protein at par-
ticular sites is important for certain functions.
A large number of mutations or variations in the human AR
gene have been identiﬁed in clinical prostate cancer specimens
and prostate cancer cell lines [20–22]. Among these, the most
characterized of the AR variants are those identiﬁed in the
prostate cancer cell lines, such as LNCaP and MDA PCa 2b.
Importantly, it is known that the N-terminal and the C-termi-
nal regions of the human AR protein are prone to amino acid
variations whereas no amino acid variations have been re-
ported in the region comprising amino acids 299–315 [21,22].
Contradictory reports in the literature concerning the
expression of AR mRNA and protein in DU-145 and PC-3 hu-
man prostate cancer cell lines, which are known to harbor
apparently normal AR gene [8,10], prompted us to investigate
whether these two prostate cancer cell lines express the ARblished by Elsevier B.V. All rights reserved.
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prostate cancer cell lines express AR mRNA and protein.
Moreover, we noted that downregulation of AR expression
in cells of PC-3 cell line resulted in decreases in levels of
p21CIP1 protein.2. Materials and methods
2.1. Cell culture and transfections
LNCaP (Lot # 1735217), PC-3 (Lot # 982225), and DU-145 (Lot #
1145858) human prostate cancer cell lines were purchased from the
American Type Culture Collection (ATCC; Manassas, VA). Cell lines
were maintained in 1640 culture medium (Invitrogen Life Technolo-
gies) supplemented with 10% (v/v) fetal bovine serum and antibiotics.
If so indicated, cells were cultured in prostate epithelial cell basal med-
ium (PrEGM; Cambrex, Walkersville, MD) supplemented with 10%
charcoal-stripped fetal bovine serum (Sigma). Cells were either treated
with the indicated concentration of 5-a-dihydrotestosterone (DHT;
Sigma) in ethanol. PC-3 cells at 50% conﬂuence were transfected with
either an empty control plasmid or a plasmid encoding siRNA to
human AR (pKD-Androgen Receptor-v1; Upstate, Lake Placid,
NY; the AR target sense sequence: 5 0-aactccttcagcaacagcagcttcaaga-
gagctgctgttgctgaaggagtttttg-3 0) using SuperFect transfection reagent
(Qiagen). 24 h after transfection, cells were lysed and the lysates were
processed for immunoblotting.
2.2. RT-PCR
Total RNA was isolated from the indicated cells using TRIzol re-
agent (Invitrogen) as suggested by the supplier. Isolated total RNA
was ﬁrst treated with DNase to eliminate contamination of any chro-
mosomal DNA. The treated RNA (1 lg) was subjected to cDNA syn-
thesis using SuperScript First-Stand Synthesis system (Invitrogen) as
suggested by the supplier followed by PCR, using primers speciﬁc to
AR complementary DNA (see Fig. 1) or actin, and a kit from Invitro-
gen Life Technologies, as suggested by the supplier. The forward AR
primer was (2055–2077; 5 0-ACACATTGAAGGCTATGAATGTC)Fig. 1. Expression of androgen receptor mRNA is detectable in DU-
145 and PC-3 human prostate cancer cell lines. (A) A schematic
representation of the human AR cDNA (the NCBI entry number
M34233.1). The relative positions of the forward and the backward
PCR primers in the AR cDNA are shown by black arrows. (B) Total
RNA isolated from the indicated human prostate cancer cell lines was
subjected to RT-PCR as described in Section 2 using the forward
(2055–2077) and the backward (2892–2869) PCR primers speciﬁc to
the human AR cDNA or actin. As a negative control (NC), no RNA
was included in the reverse transcriptase reaction (lane 1). The PCR
products were analyzed by agarose gel electrophoresis after the
indicated number of PCR cycles.and the reverse primer was (2892–2869; 5 0-AACAGGCAGAAGA-
CATCTGAAAGG-3 0). The PCR products were analyzed by agarose
gel electrophoresis after indicated numbers of PCR cycles.
2.3. Immunoblotting
Total cell lysates were prepared using a modiﬁed RIPA protein
extraction buﬀer as described previously [23]. The lysis buﬀer was sup-
plemented with complete mini EDTA-free protease inhibitor cocktail
(Roche). Cell lysates containing approximately equal amounts of pro-
tein were subjected to immunoblotting using the optimized conditions
to detect low levels of AR protein. In brief, proteins were transferred to
Immobilon-P (pore size 0.45 lm; Millipore, Bedford, MA) transfer
membranes using the transfer buﬀer with 0.01% SDS (w/v). After the
transfer, membranes were rinsed with phosphate buﬀered saline
(PBS) and blocked with 5% non-fat dry milk in TBST (10 mM Tris–
HCl, 150 mM NaCl, 0.01% Tween-20) for 1–2 h at room temperature.
The blots were incubated overnight with anti-AR antibodies (1–2 lg/
ml) in TBST at 4 C. To block antibody, sc-816 anti-AR antibody
(5 lg) was pre-incubated with either the blocking peptide sc-816P
(50 lg) or bovine serum albumin (50 lg) in 100 ll TBST for 3 h at
4 C. Antipeptide antibodies to AR (sc-816, sc-7305, and sc-815) and
p21CIP1 (sc-397) were purchased from Santa Cruz (Santa Cruz, CA).
Monoclonal antibodies to actin were from Sigma. The blocking pep-
tide (sc-816P) for anti-AR antibody sc-816 was purchased from Santa
Cruz.
2.4. Reporter assays
Cells were transfected with pARE-e1b-luc (ARE-luc; Ref. [24]; re-
porter plasmid was generously provided Dr. N. Weigel, Baylor College
of Medicine, Houston, TX) or p21-luc-reporter plasmid along with
pRL-TK (Promega, plasmids in 5:1 ratio) reporter plasmid using
SuperFect transfection reagent (Qiagen). 40–45 h after transfection,
dual luciferase reporter assays were performed as described previously
[25].
2.5. Indirect immunoﬂuorescence
Cells cultured on glass coverslips in a six-well plate were either left
untreated or treated with DHT (10 nM) for 24 h. Cells were ﬁxed
and processed for indirect immunoﬂuorescence microscopy as de-
scribed previously [25]. The antipeptide sc-7305 conjugated to rhoda-
mine ﬂuorochrome (Santa Cruz) detected the AR protein.3. Results
3.1. Expression of AR mRNA is detectable in DU-145 and PC-3
cells
To test whether DU-145 and PC-3 human prostate cancer
cell lines express AR mRNA, we chose to compare the stea-
dy-state levels of AR mRNA in DU-145 and PC-3 cell lines
with LNCaP, an AR-positive, cell line. As shown in Fig. 1A,
using a pair of primer speciﬁc to the AR cDNA, we were able
to detect the expression of AR mRNA in LNCaP and DU-145
cells after 30 cycles of PCR (Fig. 1B). However, levels of AR
mRNA in DU-145 cells were about 50% lower than the
LNCaP cells. Interestingly, additional PCR cycles allowed us
to detect the expression of AR mRNA in PC-3 cells, indicating
that the steady-state levels of AR mRNA in PC-3 cells are rel-
atively much lower than the DU-145 and LNCaP cells. To
conﬁrm the identity of the RT-PCR DNA fragments from
the DU-145 and PC-3 cells in the above experiments, we also
performed sequencing of the PCR fragments. Sequencing of
the PCR DNA fragments and subsequent sequence compari-
sons with the human AR cDNA sequences in the NCBI and
other public data bases revealed that the RT-PCR products
from the DU-145 and PC-3 cells were indeed derived from
the human AR mRNA. These observations are consistent with
the previous observations [8–12] that the expression of AR
2296 F. Alimirah et al. / FEBS Letters 580 (2006) 2294–2300mRNA is detectable in DU-145 and PC-3 prostate cancer cell
lines.
3.2. Antipeptide antibodies to human AR detect the expression of
AR in prostate cancer cell lines by immunoblotting
Our ability to detect the expression of AR mRNA in
DU-145 and PC-3 cell lines prompted us to investigate the
expression of AR protein in these two prostate cancer cell
lines. Because these two cell lines were reported to be negative
for the expression of AR protein [5–7], we considered the fol-
lowing two possibilities that: (i) these two prostate cancer cell
lines express relatively low levels of the AR protein; and/or (ii)
mutations or variations within the amino acid sequence of the
AR protein, which is expressed in these two prostate cancer
cell lines, could contribute to the lack of detection of the AR
protein by available antibodies.
To detect the expression of relatively low levels of AR pro-
tein, which is of relatively large size (110–112 kDa), we ﬁrst
chose to optimize immunoblotting conditions. For this pur-
pose, we chose to use antipeptide antibody sc-7305 that was
raised against the non-variable region (amino acids 299–315)
of the human AR protein (see Fig. 2A). As described in Sec-
tion 2, inclusion of 0.01% (w/v) sodium dodecyl sulfate
(SDS) in the protein transfer buﬀer signiﬁcantly improved
our ability to detect diﬀerent isoforms (110 and 112 kDa)
of the AR protein in extracts derived from LNCaP cells by
immunoblotting (Fig. 2B, compare lane 4 with 1). Moreover,
under these immunoblotting conditions, we were able to detect
a prominent protein band of 108–110 kDa in DU-145 and
PC-3 cell extracts (Fig. 2B, compare lane 5 with 2 or 6 with
3). Interestingly, the protein band migrated slightly faster than
the two AR isoforms detected in extracts from LNCaP cells
(Fig. 2B, compare lane 5 with 4). Importantly, the inclusionFig. 2. Antipeptide antibodies to human AR protein detect the expression of
transfer buﬀer improves the sensitivity to detect the expression of AR protein
the human AR protein (from the NCBI database entry number P10275) an
terminus) of the peptides (1–20, 299–315, and 900–919 amino acid residues)
were raised. The known amino acid variations in the human AR protein are s
sequence in the NCBI ﬁle P10275. (B) Total cell extracts from LNCaP (lan
subjected to SDS–PAGE and proteins were transferred to membrane in the
3 h. The proteins transferred to membrane were detected by immunoblotting
described in panel A above) from the indicated human prostate cancer cell lin
816 (directed against the N-terminal variant epitope) directly (top panel) or a
was also subjected to immunoblotting using antibodies to actin.of 0.01% SDS in the transfer buﬀer did not have any apprecia-
ble eﬀect on the detection of b-actin protein in these three cell
lines (Fig. 2B).
To identity the protein band that was detected in extracts
from DU-145 and PC-3 cells in the above immunoblotting
experiments (using sc-7305 anti-AR antibody), we chose to
use another antipeptide antibody (sc-816; directed against the
N-terminal peptide 1–20) to the human AR protein, for which
the corresponding antigen peptide is available commercially.
As shown in Fig. 2C, pre-incubation of the anti-AR antibody
with the antigen peptide (against which the antibodies were
raised), but not the puriﬁed bovine serum albumin, completely
inhibited the detection of the AR protein in LNCaP as well as
in DU-145 and PC-3 cell lines (Fig. 2C). Together, these obser-
vations demonstrated that the protein band that was detected
by two antipeptide antibodies (sc-7305 and sc-816) to the
human AR protein is indeed the AR protein.
Next, to investigate the possibility that mutations or varia-
tions within the amino acid sequence of the AR protein could
contribute to the lack of detection of the AR protein in DU-
145 and Pc-3 cell lines, we chose antipeptide antibodies (sc-
816, sc-7305, and sc-815) directed against peptides derived
from three distinct regions of the human AR protein
(Fig. 2A): the N-terminal region (a variant region), central re-
gion (a non-variant region), and the C-terminal region (a
highly variant region), and compared the ability of these three
antibodies to detect AR protein in immunoblotting. As shown
in Fig. 3A, the three antipeptide AR antibodies detected the
expression of the human AR protein isoforms in extracts de-
rived from HEK293 cells that were transfected with a plasmid
(pCMV-AR) encoding the human AR protein, but not in cells
transfected with an empty vector (pCMV) (compare lane 2
with 1). Moreover, consistent with the previous report thatAR protein in prostate cancer cell lines and inclusion of SDS in protein
in LNCaP cells by immunoblotting. (A) A schematic representation of
d the relative positions (NT, N-terminus; CR, central region; CT, C-
against which the antibodies (sc-816, sc-7305, and sc-815, respectively)
hown. The amino acid residues are numbered based on the AR protein
es 1 and 4), DU-145 (lanes 2 and 5), and PC-3 (lanes 3 and 6) were
absence (lanes 1–3) or the presence (lanes 4–6) of 0.01% (w/v) SDS for
using antibodies to AR (sc-7305). (C) Total cell extracts (prepared as
es were subjected to immunoblotting using the antipeptide antibody sc-
fter pre-incubation with antigen peptide (middle panel). The same blot
Fig. 3. Antipeptide antibodies directed against three distinct regions of the human AR protein detect the expression of AR protein. (A) Total cell
lysates from HEK293 cells either transfected with an empty vector (lane 1) or a plasmid encoding the human AR protein (lane 2) were analyzed by
immunoblotting using the indicated antipeptide antibodies to human AR or actin protein. (B) Total extracts from the indicated human prostate
cancer cell lines either left without any treatment (lane 1) or treated with DHT (10 nM; lane 2) for 24 h were subjected to immunoblotting using the
indicated antipeptide antibodies to human AR or actin protein. (C) Total extracts from LNCaP (lanes 2 and 3), DU-145 (lanes 4 and 5), and PC-3
(lanes 6 and 7) cell lines either left without any treatment (lanes 2, 4, and 6) or treated with DHT (10 nM; lanes 3, 5, and 7) for 24 h were subjected to
immunoblotting using the indicated antipeptide antibody to the human AR or actin protein. Total cell extracts from HEK293 cells served as a
negative control (NC; lane 1).
F. Alimirah et al. / FEBS Letters 580 (2006) 2294–2300 2297in LNCaP cells AR protein is detected as two isoforms with
apparent molecular masses of 110 and 112-kDa [18], we also
detected two isoforms of AR protein using antipeptide anti-
bodies directed against the N-terminus or the conserved region
of the AR protein. Additionally, we noted that the antipeptide
antibody directed against highly variable C-terminal region of
the human AR protein, detected only one isoform of the AR
protein (Fig. 3A). Together, these observations suggested that
three antipeptide AR antibodies could detect the AR protein
under our optimized immunoblotting conditions; however,
the C-terminal antibody could detect only one isoform of the
AR protein.
Next, using the above three antipeptide antibodies to AR,
we analyzed the expression of AR protein in cell extracts de-
rived from LNCaP, DU-145, and PC-3 cells either left without
any treatment or treated with 5-a-dihydrotestosterone (DHT),
a ligand and a potent inducer of AR protein [26]. As shown in
Fig. 3B, the AR antibodies directed against the N-terminal
peptide (amino acids 1–20) or the peptide derived from the
central region (amino acids 299–315) detected the expression
of AR in all three-cell lines. However, the antibodies directed
against the C-terminal peptide (amino acids 900–919) of AR
protein detected the expression of AR protein strongly in
LNCaP cells, but albeit weakly in DU-145 and PC-3 cells.
Importantly, the treatment of cells with DHT resulted in
1.5–2-fold increases in AR protein levels in all three cell lines.
Because in the above experiments the C-terminal antibody to
AR weakly detected the AR protein in DU-145 and PC-3 cells,
we explored whether polymorphisms or mutations in the AR
gene that encode the C-terminal region of AR protein could
account for a weak interaction between the antibody and the
AR protein. Therefore, we isolated and cloned the 3 0-end of
the AR gene by RT-PCR, which encodes the C-terminal end
of the AR protein comprising the epitope (amino acids 900–919) recognized by the C-terminal antibody (Fig. 2A), from
the LNCaP, DU-145 and PC-3 cells and performed DNA-
sequencing. The sequence analyses of AR coding region from
all three prostate cancer cell lines did not reveal any polymor-
phism/mutation in the AR cDNA that could account for the
lack of detection of AR protein by the C-terminal antibody
in extracts from the DU-145 and PC-3 cells (data not shown).
This observation raises the possibility that the cell line-depen-
dent post-translational modiﬁcations, such as phosphorylation
and/or acetylation, in AR protein could account for the lack of
detection of AR protein by the C-terminal antibody in DU-145
and PC-3 cells (Fig. 3B).
The antipeptide antibody sc-7305 (directed against a non-
variant region of the human AR protein; see Fig. 2A) was able
to detect the expression of AR protein in all three prostate can-
cer cell lines relatively better than the two other antipeptide
antibodies (Fig. 3B). Therefore, we chose this particular anti-
body to compare the relative levels of AR protein in LNCaP,
DU-145, and PC-3 prostate cancer cell lines. Consistent with
AR mRNA levels in DU-145 and PC-3 cell lines (Fig. 1B),
the relative levels of AR protein that were detected in DU-
145 or PC-3 cells were signiﬁcantly lower than those detected
in the LNCaP cells (Fig. 3C). Together, these observations
indicated that DU-145 and PC-3 prostate cancer cell lines ex-
press detectable levels of AR protein and three antipeptide
antibodies to human AR protein diﬀer with respect to their
ability to detect the expression of AR protein in these three
prostate cancer cell lines.
3.3. Treatment of prostate cancer cell lines with DHT results in
nuclear localization of AR and stimulation of the
AR-mediated transcription in LNCaP cells
Expression of AR protein in cells of DU-145 and PC-3 cell
lines prompted us to determine whether the AR protein is
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dent transcription factor [1,26], we ﬁrst sought to determine
whether DHT treatment of DU-145 and PC-3 cells has any ef-
fect on nuclear localization of AR protein. As shown in
Fig. 4A, we could detect the expression of AR protein in un-
treated control cells of LNCaP, DU-145 and PC-3 cell lines.
Interestingly, AR was localized primarily in the cytoplasm of
LNCaP and DU-145 cells. However, consistent with the previ-
ous report [12], AR was detected both in the cytoplasm and in
the nucleus of PC-3 cells. Additionally, fractionation of PC-3
cells into cytoplasmic and nuclear fractions, followed by
immunoblotting for AR protein, indicated that the AR was
roughly equally distributed between the nuclear and the cyto-
plasmic fractions (data not shown). Furthermore, consistent
with the previous report [12], we noted that not all PC-3 cells
stained positive for the expression of AR protein. Similarly,
not all DU-145 cells stained positive for the expression of
AR protein. Interestingly, DHT treatment of DU-145 and
PC-3 cells resulted in relatively brighter staining of cells for
AR protein, and among the AR-positive cells, relatively more
AR was detected in the nucleus. Together, these observations
revealed that PC-3 and DU-145 cells exhibit heterogeneity with
respect to the detection of AR protein by indirect immunoﬂu-
orescence and DHT treatment of cells resulted in appreciable
nuclear localization of AR protein in AR-positive DU-145
and PC-3 cells.
Considerable nuclear localization of AR protein in DHT
treated AR-positive DU-145 and PC-3 cells in the above exper-
iments prompted us to determine whether the AR was trans-
criptionally active. For this purpose, we compared the
activity of pARE-e1b-luc-reporter (AR-luc), an AR-responsive
reporter [24], between untreated or DHT treated cells. AsFig. 4. Treatment of LNCaP, DU-145 and PC-3 cells with androgen recep
protein and treatment of LNCaP cells with DHT results in stimulation of the
grown on glass coverslips in a six-well plate. Cells grown in the basal medium
(10 nm; right panel) for 24 h. Cells were ﬁxed and processed for indirect i
conjugated to rhodamine ﬂuorochrome. (B) Sub-conﬂuent cultures of LNCa
transfected with the AR-luc-reporter plasmid along with pRL-TK reporter pl
left without any treatment (control) or treated with DHT (10 nM) for 24 h. 48
activity. Error bars indicate the S.D.shown in Fig. 4B, treatment of DU-145 or PC-3 cells with
DHT did not result in appreciable stimulation of the activity
of the reporter. In contrast, treatment of LNCaP cells with
DHT resulted in a strong stimulation of the activity of the re-
porter (Fig. 4B). Moreover, we were unable to detect the
expression of prostate-speciﬁc antigen (PSA) in DHT un-
treated or treated DU-145 and PC-3 cells by RT-PCR. How-
ever, the expression of PSA mRNA was readily detectable in
LNCaP cells after DHT treatment (data not shown). Together,
these observations indicated that DHT treatment of DU-145
and PC-3 cells did not result in transcriptional activation of
AR-responsive genes by AR.
3.4. Knockdown of AR expression in PC-3 cells results in
downregulation of p21CIP1 protein
AR is known to upregulate the expression of p21CIP1, a well-
known inhibitor of cyclin-dependent kinases, in prostate can-
cer cell lines [27]. Consistent with this observation, we noted
that DHT treatment of PC-3 cells resulted in upregulation of
p21CIP1 levels (Fig. 5A). Because the AR-mediated trans-acti-
vation could be induced in a ligand-independent manner
[3,4], we chose to knockdown the expression of AR in PC-3
cells (because the AR was detected both in the cytoplasm
and in the nucleus of untreated PC-3 cells, see Fig. 4A) to
determine whether the expression of AR in PC-3 cells contrib-
utes to the regulation of p21CIP1. As shown in Fig 5B, transfec-
tion of cells with a negative control (si-RNA to luciferase gene)
or an empty plasmid did not result downregulation of AR pro-
tein. However, transfection of a plasmid encoding a si-RNA to
human AR resulted in 40–50% decreases in AR protein levels.
Importantly, the knockdown of AR expression in PC-3 cells
also resulted in downregulation of p21CIP1 protein levels.tor ligand (DHT) results in considerable nuclear localization of AR
activity of an AR-responsive reporter. (A) DU-145 and PC-3 cells were
were either left without any treatment (left panels) or treated with DHT
mmunoﬂuorescence using monoclonal antibodies to AR, which were
P, DU-145 or PC-3 cells were grown in the basal medium. Cells were
asmid as described in Section 2. 24 h after transfections cells were either
–50 h after transfections, cells were processed to estimate dual luciferase
Fig. 5. AR regulates the expression of p21CIP1 in PC-3 cells and knockdown of AR in PC-3 cells results in downregulation of p21CIP1. (A) Sub-
conﬂuent cultures of PC-3 cells were either left untreated or treated with DHT (10 nM) for 24 h. Total cell lysates were analyzed by immunoblotting
using antibodies speciﬁc to AR (sc-816), p21, or actin as described in Section 2. (B) Sub-conﬂuent cultures of PC-3 cells were either transfected with a
si-RNA to luciferase (a negative control, lane 1), an empty plasmid pKD (control, lane 2), or the pKD-AR-v1 plasmid allowing the expression of si-
RNA to human AR (lane 3). 72 h after transfection, cell lysates were analyzed by immunoblotting using antibodies speciﬁc to AR (sc-816), p21, or
actin. (C) Sub-conﬂuent cultures of PC-3 cells (grown in the basal medium) were either transfected with an empty pKD plasmid (control, column 1)
or the pKD-AR-v1 plasmid allowing the expression of si-RNA to human AR (column 2). 24 h after transfection, cells were transfected with p21-luc
and pRL-TK reporter plasmids as described in Section 2. 72 h after the ﬁrst transfection, cell lysates were processed for dual luciferase reporter
activities. The normalized relative luciferase activity is shown.
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sulted in 60% decrease in the activity of the p21-luc-reporter
(Fig. 5C). Together, the above observations indicated that the
expression of AR in PC-3 cells may contribute to the regula-
tion of the p21 gene expression.4. Discussion
Studies have indicated the expression of low, but detectable,
levels of AR mRNA in PC-3 prostate cancer cell line [8–12].
Additionally, using the whole cell binding assays to androgen
ligand, the expression of AR protein has been reported in both
DU-145 and PC-3 cell lines [14,15]. However, to the best of our
knowledge, there is no report of detection of AR protein in
DU-145 and PC-3 prostate cancer cell lines by immunoblot-
ting. Because DU-145 and PC-3 prostate cancer cell lines are
considered to be AR-negative [5–7], our observations that: (i)
these two cell lines express detectable levels of AR mRNA
and protein (Figs. 1, 2 and 4); (ii) levels of AR protein measur-
ably increase in these two cell lines after DHT treatment
(Fig. 3); (iii) DHT treatment of cells results in considerable nu-
clear localization of AR protein (Fig. 4); and (iv) knockdown
of the expression of AR in PC-3 cells results in downregulation
of p21CIP1protein (Fig. 5), are novel. Based on these observa-
tions, we propose that DU-145 and PC-3 prostate cancer cell
lines should be considered as AR-positive cell lines. Because
the treatment of these two cell lines with androgen ligand
(DHT) resulted in upregulation of AR protein, but did not re-
sult in stimulation of the activity of an AR-responsive reporter
gene, these two cell lines should be considered as androgen
non-responsive.
Phosphorylation of AR appears to be cell type-speciﬁc
[17,19]. Therefore, it is conceivable that the phosphorylation
status of AR in DU-145 and PC-3 cells diﬀers from the LNCaP
cell lines. Consistent with this idea, we noted that the AR pro-
tein from DU-145 and PC-3 cells migrated slightly faster than
the LNCaP protein (Figs. 2 and 3). Because ligand-induced
phosphorylation of AR protein at certain phosphorylation
sites is thought to activate and stabilize AR protein [17,19],
our observations that DU-145 and PC-3 cell lines express
AR protein will facilitate studies to determine whether diﬀer-
ences in the phosphorylation of AR protein between LNCaPand these two cell lines could account for their diﬀerences in
androgen response.
The ability of androgen receptor to regulate transcription of
target genes is dependent on cofactors, either co-activators or
co-repressors [28]. Our observation that DU-145 and PC-3
cells express detectable levels of AR protein, but fail to activate
the transcription of an AR-responsive reporter gene in re-
sponse to DHT treatment in reporter assays raise the possibil-
ity that defects in the expression and/or function of certain
co-activators or co-repressors may contribute to the lack of
transcriptional activation by AR in these two AR-positive cell
lines. Consistent with this idea, it has been reported that the
expression of AR co-activators is diﬀerentially regulated
among LNCaP, DU-145, and PC-3 cells [12,29,30]. Our obser-
vation that DU-145 and PC-3 cells express AR protein will
facilitate studies to identify the molecular mechanisms that
contribute to the AR non-responsiveness to androgens in these
two cell lines.
Levels of AR mRNA in DU-145 cells were 50% lower than
LNCaP cells (Fig. 1B). However, the AR protein levels in DU-
145 cells were signiﬁcantly lower than LNCaP cells (Fig. 3C),
raising the possibility that post-transcriptional mechanisms
regulate the levels of AR protein in DU-145 cells. Further
work is in progress to identify these molecular mechanisms.
Ectopic expression of AR in PC-3 cell line results in inhibi-
tion of cell proliferation [31]. Because androgen signaling
through the AR is known to upregulate the expression of
p21CIP1 [27], our observations that knockdown of AR expres-
sion in PC-3 cells results in downregulation of p21 protein war-
rant further investigation to determine whether increased
expression of AR in DU-145 and PC-3 cells results in inhibi-
tion of cell growth through upregulation of p21CIP1 expression.
A large number of mutations or variations in the AR gene
have been identiﬁed in clinical prostate cancer specimens and
prostate cancer cell lines [20–22]. Among these, the most char-
acterized of the AR variants are those identiﬁed in the prostate
cancer cell lines, such as LNCaP and MDAPCa2b. However, a
large number of AR variants remain uncharacterized. Our cur-
rent observations that we were unable to detect the expression
of AR protein in DU-145 and PC-3 cells using antipeptide
antibodies directed against the C-terminal variable region of
the human AR protein raise the possibility that mutations or
variations in the AR gene in these two prostate cancer cell lines
2300 F. Alimirah et al. / FEBS Letters 580 (2006) 2294–2300(and other prostate cancer cells) may make it diﬃcult to detect
the expression of AR protein. Therefore, antipeptide antibod-
ies directed against the non-variant region of the AR protein
should allow the detection of AR expression in prostate cancer
cell lines and the prostate tumors.
In summary, our observations will serve as basis to under-
stand the regulation and role of AR protein in DU-145 and
PC-3 prostate cancer cell lines. Importantly, these studies will
help in elucidation of the role of AR in the development and
progression of androgen-independent human prostate cancers.
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